"We may be witnessing the beginning of an entirely new way of treating cancer," expert say ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

Merck. Moderna & Merck announce 5-year data for intismeran autogene in combination with KEYTRUDA (pembrolizumab) demonstrated sustained improvement in recurrence-free survival in patients with ...

Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support ...

Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed ...

The intismeran/pembrolizumab combination significantly improved relapse-free and distant metastasis-free survival in advanced ...

FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.

A case report describes a child with B-ALL who recovered from probable blinatumomab-associated lung injury and completed a ...

In an exploratory analysis of 20 participants switching from ocrelizumab, BRIUMVI treatment was associated with increased regulatory T cells and decreased inflammatory monocytes at Week 12, suggesting ...

The FDA approved Hibsago (bepirovirsen; GSK), the first antisense oligonucleotide for chronic hepatitis B, for use with a nucleos (t)ide analogue in adults without cirrhosis, the agency announced ...

Merck and Moderna's Phase 3 melanoma vaccine reduced recurrence or death by 42%, with no clear effect in the first six months ...

Should Personalized mRNA Vaccines Be Benchmarked Against Adjuvant Pembrolizumab Alone? / cancer, esmo 2026, ESMO 26, Mario ...